Cerenome is trading at $1.80, up 10.09%, after announcing an in-network agreement with Florida Blue.
- Announced October 8, 2026, the agreement covers CNSide tumor-cell enumeration and molecular-profile tests, adds approximately 6 million covered lives, and raises contracted payer access to approximately 164 million.
- It is the first payer agreement to include both tests. Healthcare and major indexes were under pressure, making the company-specific announcement the clearer catalyst.
- Available sources do not provide reliable live volume data.